Expert Perspectives on a 75-Year-Old Woman With Relapsed/Refractory Follicular Lymphoma - Episode 1
Loretta Nastoupil, MD, reviews the case of a 75-year-old woman with relapsed/refractory follicular lymphoma (R/R FL).
Loretta Nastoupil, MD: Hi, I’m Dr Loretta Nastoupil from the University of Texas MD Anderson Cancer Center. Today, I’ll be discussing a 75-year-old woman with relapsed/refractory follicular lymphoma. She has a 3-month history of fatigue, occasional fevers, decreased appetite, and an approximately 12-lb weight loss. Past medical history is notable for controlled hypertension, osteoporosis, and hyperlipidemia, which is managed with diet and exercise. On examination, she has palpable bilateral axillary and cervical nodes, approximately 3 cm in both axillae and 2 cm in the cervical nodes. Her spleen is palpable 4 cm below the left costal margin.
Further work-up included laboratory tests with an ANC [absolute neutrophil count] of 1.6 per mm3; total white blood cell count of 11.4 per mm3; hemoglobin of 9.8 g/dL; platelets were 98 per mm3; LDH [lactate dehydrogenase] of 325 U/L, which is higher than the upper limit of normal; beta-2 microglobulin was 3.7 μg/mL; and the hepatitis panel was negative. This patient underwent an excisional biopsy, revealing a CD20-positive, CD10-positive, and BCL2 grade 2 follicular lymphoma. A bone marrow biopsy was pursued to complete her staging work-up, revealing a paratrabecular lymphoid aggregate, 42% involved, with a phenotype consistent with follicular lymphoma. Cytogenetics reveal translocation (14;18). This patient also underwent molecular testing, revealing an EZH2 mutation. PET [positron emission tomography]/CT reveals the known bilateral axillary and left cervical adenopathy, as well as mediastinal adenopathy. The largest lymph node was 4.6 cm. This patient is stage IV, with an ECOG [performance status] of 1. For the FLIPI [Follicular Lymphoma International Prognostic Index] score, she has age, stage, hemoglobin, and LDH. It’s a FLIPI score of 4, so it’s a high-risk FLIPI case.
Her treatment history included bendamustine and rituximab times 6 cycles, and she achieved a partial response. She then pursued maintenance rituximab. Twenty-four months later, she complained of left upper quadrant discomfort, loss of appetite, fevers, and new onset pruritis that was insatiable. She was started on antibiotics, given concerns for potential infection contributing to her presenting symptoms. Without resolution of symptoms, imaging was pursued and a PET/CT revealed concerns for progressive disease. A biopsy was pursued and confirmed relapsed follicular lymphoma. She was then initiated on second-line therapy, which consisted of R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone]. She completed 6 cycles and continued on maintenance for 2 years. Unfortunately, 12 months later, she had recurrence of these symptoms. Imaging was also worrisome for recurrent lymphoma. At this point, she was third line, and she initiated tazemetostat, 800 mg orally, twice daily.
To summarize, as a 75-year-old woman who presents with these symptoms and peripheral adenopathy, she has advanced stage disease and high-risk FLIPI. She completed 6 cycles of BR [bendamustine, rituximab]. She had a first recurrence. At that time, she was treated with R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone]. There was a shorter remission duration, similar to what we know to be consistent in relapsed follicular lymphoma. In the third-line space, she was started on tazemetostat.
This transcript has been edited for clarity.
Case: A 75-Year-Old Woman With Relapsed/Refractory Follicular Lymphoma